Tecan Group AG · SIX:TECN

Tecan — H1 2015 Earnings Presentation

29 slides from Tecan's earnings presentation, Aug 12, 2015

  1. Slide 1: Half Year Results 2015

    Zurich, August 12th 2015 Half Year Results 2015 Analyst & Media Conference Call Tecan Group

  2. Slide 2: Speakers

    Speakers Dr. David Martyr, CEO Dr. Rudolf Eugster, CFO

  3. Slide 3: Agenda

    Tecan Half Year Results 2015 / August 12th 2015 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p3

  4. Slide 4: Financial Performance H1 2015

    Tecan Half Year Results 2015 / August 12th 2015 Financial Performance H1 2015 • Double-digit sales growth; Partnering Business growing by 30% • Recurring revenues reaching 41% of total sales, including strong performance of IBL International • Order Entry growing with double-digit rate; benefiting f

  5. Slide 5: Operating Highlights H1 2015

    Tecan Half Year Results 2015 / August 12th 2015 Operating Highlights H1 2015 • Delivery ramp-up of instruments for key customers in the Partnering Business • Launch of second application-specific Fluent™ solution to simplify automated compound management for drug discovery • Launch of next-generatio

  6. Slide 6: Agenda

    Tecan Half Year Results 2015 / August 12th 2015 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p6

  7. Slide 7: H1 2015 Order Entry and Sales Performance

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Order Entry and Sales Performance Order Entry H1 225 220.1 • Order Entry H1 2015 vs. H1 2014 • +11.9% in Swiss Francs 200 196.6 • +14.6% in local currencies • Organic +9.4% in local currencies 175 • Order backlog with double-digit % increase CH

  8. Slide 8: H1 2015 Segment Sales

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Segment Sales Sales (in CHF millions) 110.0 107.5 100.9 Life Sciences Business: 92.4 • Sales up by 10.7% in local currencies (LC) 90.0 and 6.6% in CHF 2014 • Organic sales development of +0.5% in LC 2015 71.1 70.0 • Order Entry clearly exceeded

  9. Slide 9: H1 2015 Regional Sales Development

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Regional Sales Development YoY % +9.6% in LC YoY % -3.1% in CHF YoY % Europe: +21.5% in LC +12.6% in LC • IBL International main driver behind growth Others +12.9% in CHF +18.3% in CHF in Life Sciences Business 2% Asia • Partnering Business wit

  10. Slide 10: H1 2015 Gross Profit

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Gross Profit Gross Profit (in CHF millions) 100 97.0 • Gross profit amounted to CHF 97.0m 95 • CHF 9.7m or 11.1% higher than H1 2014 90 87.3 85 • Gross profit margin down by 230 bps (-) Mix impact: more sales from Partnering 80 2014 2015 Busine

  11. Slide 11: H1 2015 Cost Structure

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Cost Structure Operating Expenses (% = as a % of sales) • Operating Expenses grew slower than sales 80 71.8m 65.3m (35.9%) (37.9%) 18.6 • Sales & Marketing leverage from investments 60 18.5 (9.3%) in 2014 (10.7%) 20.1 40 17.2 (10.0%) (10.0%) •

  12. Slide 12: H1 2015 EBITDA and EBIT

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 EBITDA and EBIT EBIT and EBITDA (in CHF millions) 35 32.6 • EBITDA grew faster than sales 30 26.8 • CHF 5.8m or 21.4% above H1 2014 25.3 EBIT 25 22.3 • EBITDA margin +70 bps to 16.3% EBITDA 20 • EBIT, including IBL International, increased 15 2

  13. Slide 13: H1 2015 Segment Profitability

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Segment Profitability EBIT (in CHF millions) 20 Life Sciences Business: 17.4 14.8 • EBIT margin at 9.8% 15 11.3 (-) Mix impact with higher costs and investments 11.3 10 2014 during the launch phase of new instruments 2015 (-) Consolidation of I

  14. Slide 14: H1 2015 Net Profit

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Net Profit Net Profit (in CHF millions) • Net profit grew significantly faster than sales 26.0 25 • CHF 7.4m or 39.7% above H1 2014 • Positive volume effect 20 18.6 • Below EBIT line: 15 (+) Improved financial result attributable to 2014 2015 c

  15. Slide 15: H1 2015 Basic Earnings per Share

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Basic Earnings per Share Basic Earnings per Share 2.40 2.31 • Earnings per share increased by 37.5% to CHF 2.31 2.20 2.00 • Average number of shares outstanding: CHF / share 11.2m (H1 2014: 11.1m) 1.80 1.68 1.60 1.40 2014 2015 p 15

  16. Slide 16: H1 2015 Cash Flow

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Cash Flow 14.4 171.3 35.1 -6.9 128.7 Cash at end of From Operations From Investments From Financing1 Cash at end of 2014 June 2015 • Cash flow from operations increased to CHF 35.1m or 17.6% of sales (H1 2014: CHF 16.2m) • Strong cash generatio

  17. Slide 17: H1 2015 Key Figures

    Tecan Half Year Results 2015 / August 12th 2015 H1 2015 Key Figures CHF m 2014 2015 Δ in % Order Entry 196.6 220.1 +11.9% Sales 172.0 200.0 +16.2% Sales in local currencies 168.2 200.0 +18.9% Gross Profit 87.3 97.0 +11.1% in % of sales 50.8% 48.5% R&D 17.2 20.1 +16.6% in % of sales 10.0% 10.0% EBIT

  18. Slide 18: Agenda

    Tecan Half Year Results 2015 / August 12th 2015 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p 18

  19. Slide 19: Priorities for 2015

    Tecan Half Year Results 2015 / August 12th 2015 Priorities for 2015 Driving growth in Life Sciences Business: focus on launch of new products, continued IBL integration and China expansion Continue to support Partnering Business customers with delivery ramp-up and continued development of new produc

  20. Slide 20: Major Platform Launches: Fluent

    Tecan Half Year Results 2015 / August 12th 2015 Major Platform Launches in Two Product Lines Fluent™* Update • Product announcements: Jun 2014 -- Cell Biology Feb 2015 – Compound Management Feb 2015 – New modules for increased general purpose use Aug 2015 – Air displacement pipetting Aug 2015 – New

  21. Slide 21: Major Platform Launches: Spark

    Tecan Half Year Results 2015 / August 12th 2015 Major Platform Launches in Two Product Lines Spark™* Update • Launch of the Spark™ 10M next-generation reader platform in February • Designed for cell biology and genomics customers • Greater flexibility, increased speed and productivity • Launch of ad

  22. Slide 22: Priorities for 2015

    Tecan Half Year Results 2015 / August 12th 2015 Priorities for 2015 Driving growth in Life Sciences Business: focus on launch of new products, continued IBL integration and China expansion Continue to support Partnering Business customers with delivery ramp-up and continued development of new produc

  23. Slide 23: Supporting Significant Delivery Ramp-Up: Dako Omnis

    Tecan Half Year Results 2015 / August 12th 2015 Supporting Significant Delivery Ramp-Up Dako Omnis Update • Continued global commercial uptake • Agilent have reported record instrument placements for several quarters in a row • Dako continuing to add new assays and panels to Omnis platform Advanced

  24. Slide 24: Supporting Significant Delivery Ramp-Up: ORTHO VISION

    Tecan Half Year Results 2015 / August 12th 2015 Supporting Significant Delivery Ramp-Up ORTHO VISION™* Update • Significant increase in serial production to support commercial rollout in Europe, Japan and Australia • Ortho-Clinical Diagnostics obtained Health Canada approval for the North American v

  25. Slide 25: Priorities for 2015

    Tecan Half Year Results 2015 / August 12th 2015 Priorities for 2015 Driving growth in Life Sciences Business: focus on launch of new products, continued IBL integration and China expansion Continue to support Partnering Business customers with delivery ramp-up and continued development of new produc

  26. Slide 26: Agenda

    Tecan Half Year Results 2015 / August 12th 2015 Agenda • Introduction • Financial Results • Priorities • Outlook • Questions and Answers p 26

  27. Slide 27: Outlook for 2015 Confirmed

    Tecan Half Year Results 2015 / August 12th 2015 Outlook for 2015 Confirmed Sales Double-digit sales growth in local currencies Profitability EBITDA margin to increase by more than 100 bps Based on average FX rates of: 1.05 EUR/CHF and 0.92 USD/CHF 27p 27 pp27

  28. Slide 28: Q&A

    Tecan Half Year Results 2015 / August 12th 2015 Q&A IR iPad App News, financial reports, presentations, videos and more Next Events 2016: March 15: Full Year Results 2015 April 13: Annual Shareholder Meeting Contact Martin Braendle Vice President, Communications & IR Phone: +41 (0) 44 922 84 30 inve

  29. Slide 29: Thank you for your attention

    Thank you for your attention Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solution

Tecan Group — H1 2015 Earnings Presentation on 6ix